Methylomics is a cancer diagnostics company that specializes in cancer diagnosis and monitoring by genome wide methylation profiling. A unique and inexpensive technique called MeD-seq, developed by the founders of Methylomics, helped us to create the extensive DNA methylation cancer atlas, Methyl-Me. Methyl-Me consists of MeD-seq, a database and AI algorithm and can be used for diagnosis, treatment monitoring and determining the origin of the tumor. The MeD-seq technology also helped us discover two proprietary pan-gynecological markers that can be used for the rapid detection of all types of gynecological cancers at once with our MeD-Scan assay.

𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 
•	Methylation profiling and marker discovery: Partner with us on innovative research projects and explore the diagnostic potential of methylation markers.
•	Diagnostic assay development service: Collaborate with our experts to develop rapid and inexpensive methylation assays for the detection of specific cancer types.
•	Clinical trials: Join forces in conducting clinical trials. Strengthen the 
clinical utility of methylation sequencing in personalized medicine for diagnosis & treatment monitoring of cancers and other diseases.

Methylomics

Org chart

Teams

Offices